Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Goldstein

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistanceBarry J Goldstein
Reviews in Cardiovascular Medicine|December 12, 2003
Insulin resistance: from benign to type 2 diabetes mellitusBarry J Goldstein
The Journal of Clinical Endocrinology and Metabolism|April 6, 2007
Clinical translation of "a diabetes outcome progression trial": ADOPT appropriate combination oral therapies in type 2 diabetesBarry J Goldstein
Clinical Therapeutics|September 21, 2002
Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs)Barry J Goldstein
BMJ (Clinical Research Ed.)|May 12, 2011
Journal’s withdrawal of article. Concerns about methods usedBarry J Goldstein
The American Journal of Cardiology|September 17, 2002
Insulin resistance as the core defect in type 2 diabetes mellitusBarry J Goldstein
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Intensive insulin therapy regimens: is there a difference in patient satisfaction?Barry J Goldstein
Diabetes/Metabolism Research and Reviews|March 29, 2002
Differentiating members of the thiazolidinedione class: a focus on efficacyBarry J Goldstein
Clinical and Translational Science|May 27, 2009
Inflammatory signaling: another drug target to improve glycemic control in type 2 diabetesBarry J Goldstein
The Journal of Clinical Endocrinology and Metabolism|June 8, 2004
Adiponectin: A novel adipokine linking adipocytes and vascular functionBarry J Goldstein, Rosario Scalia
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistanceBarry J Goldstein
Reviews in Cardiovascular Medicine|December 12, 2003
Insulin resistance: from benign to type 2 diabetes mellitusBarry J Goldstein
The Journal of Clinical Endocrinology and Metabolism|April 6, 2007
Clinical translation of "a diabetes outcome progression trial": ADOPT appropriate combination oral therapies in type 2 diabetesBarry J Goldstein
Clinical Therapeutics|September 21, 2002
Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs)Barry J Goldstein
BMJ (Clinical Research Ed.)|May 12, 2011
Journal’s withdrawal of article. Concerns about methods usedBarry J Goldstein
The American Journal of Cardiology|September 17, 2002
Insulin resistance as the core defect in type 2 diabetes mellitusBarry J Goldstein
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Intensive insulin therapy regimens: is there a difference in patient satisfaction?Barry J Goldstein
Diabetes/Metabolism Research and Reviews|March 29, 2002
Differentiating members of the thiazolidinedione class: a focus on efficacyBarry J Goldstein
Clinical and Translational Science|May 27, 2009
Inflammatory signaling: another drug target to improve glycemic control in type 2 diabetesBarry J Goldstein
The Journal of Clinical Endocrinology and Metabolism|June 8, 2004
Adiponectin: A novel adipokine linking adipocytes and vascular functionBarry J Goldstein, Rosario Scalia
Pageof 8